<?xml version='1.0' encoding='utf-8'?>
<document id="27840091"><sentence text="Potential accumulation of protopanaxadiol-type ginsenosides in six-months toxicokinetic study of SHENMAI injection in dogs."><entity charOffset="26-41" id="DDI-PubMed.27840091.s1.e0" text="protopanaxadiol" /><entity charOffset="47-59" id="DDI-PubMed.27840091.s1.e1" text="ginsenosides" /><entity charOffset="97-104" id="DDI-PubMed.27840091.s1.e2" text="SHENMAI" /><pair ddi="false" e1="DDI-PubMed.27840091.s1.e0" e2="DDI-PubMed.27840091.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27840091.s1.e0" e2="DDI-PubMed.27840091.s1.e1" /><pair ddi="false" e1="DDI-PubMed.27840091.s1.e0" e2="DDI-PubMed.27840091.s1.e2" /><pair ddi="false" e1="DDI-PubMed.27840091.s1.e1" e2="DDI-PubMed.27840091.s1.e1" /><pair ddi="false" e1="DDI-PubMed.27840091.s1.e1" e2="DDI-PubMed.27840091.s1.e2" /></sentence><sentence text="SHENMAI injection (SMI), derived from famous Shen Mai San, is a herbal injection widely used in China" /><sentence text=" Ginsenosides are the major components of SMI" /><sentence text=" To monitor the exposure level of SMI during long-term treatment, a 6-month toxicokinetic experiment was performed" /><sentence text=" Twenty-four beagle dogs were dived into four groups (n = 6 in each group): a control group (0" /><sentence text="9% NaCl solution) and three SMI groups (2, 6 or 3 mg/kg)"><entity charOffset="3-7" id="DDI-PubMed.27840091.s6.e0" text="NaCl" /></sentence><sentence text=" The dogs were i" /><sentence text="v" /><sentence text=" infused with vehicle or SMI daily for 180 d" /><sentence text=" Blood samples for analysis were collected at specific time points as follows: pre-dose (0 h); at 10, 30, and 60 min during infusion; and at 10, 30, 60, 90, 120, 240, and 300 min post-administration" /><sentence text=" Concentrations of ginsenosides Rb1, Rb2, Rc, Rd, Re, Rf, and Rg1 in the plasma were determined simultaneously by liquid chromatography-tandem mass spectrometry"><entity charOffset="19-35" id="DDI-PubMed.27840091.s11.e0" text="ginsenosides Rb1" /></sentence><sentence text=" Non-compartmental parameters were further calculated and analyzed" /><sentence text=" Significant differences were found between the kinetic behavior of 20(S)-protopanaxadiol-type (PPD-type) and 20(S)-protopanaxatriol-type (PPT-type) ginsenosides"><entity charOffset="68-89" id="DDI-PubMed.27840091.s13.e0" text="20(S)-protopanaxadiol" /><entity charOffset="110-132" id="DDI-PubMed.27840091.s13.e1" text="20(S)-protopanaxatriol" /><entity charOffset="149-161" id="DDI-PubMed.27840091.s13.e2" text="ginsenosides" /><pair ddi="false" e1="DDI-PubMed.27840091.s13.e0" e2="DDI-PubMed.27840091.s13.e0" /><pair ddi="false" e1="DDI-PubMed.27840091.s13.e0" e2="DDI-PubMed.27840091.s13.e1" /><pair ddi="false" e1="DDI-PubMed.27840091.s13.e0" e2="DDI-PubMed.27840091.s13.e2" /><pair ddi="false" e1="DDI-PubMed.27840091.s13.e1" e2="DDI-PubMed.27840091.s13.e1" /><pair ddi="false" e1="DDI-PubMed.27840091.s13.e1" e2="DDI-PubMed.27840091.s13.e2" /></sentence><sentence text=" Increasing in the exposure level of PPD-type ginsenosides was observed in dogs during the experiment" /><sentence text=" Therefore, PPD-type ginsenosides are closely related to the immunity modulation effect of SMI"><entity charOffset="21-33" id="DDI-PubMed.27840091.s15.e0" text="ginsenosides" /></sentence><sentence text=" Increased PPD-type ginsenoside exposure level may present potential toxicity and induce drug-drug interaction risks during SMI administration"><entity charOffset="20-31" id="DDI-PubMed.27840091.s16.e0" text="ginsenoside" /></sentence><sentence text=" As such, PPD-type ginsenoside accumulation must be carefully monitored in future SMI research"><entity charOffset="19-30" id="DDI-PubMed.27840091.s17.e0" text="ginsenoside" /></sentence><sentence text="" /></document>